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blocking ERK1/2 and p38 MAP kinases (7). [6]-Gingerol, a pungent 
ingredient present in ginger (Zingiber ofﬁcinale Roscoe, Zingiberaceae), 
inhibited TPA-induced tumor necrosis factor-alpha production, ornithine 
decarboxylase activity, and skin tumor promotion in female ICR mice 
(8). Topically applied [6]-gingerol inhibited TPA-induced phosphoryla-
tion of p65 at Ser 536 and its interaction with the coactivator cAMP 
response element binding protein-binding protein(CBP/p300) in mouse 
skin, thereby rendering NF-κB transcriptionally inactive (9). The NF-κB 
inhibitory effects of [6]-gingerol appears to be associated with inhibition 
of p38 MAP kinase. [6]-Gingerol also inhibited anchorage-indepen-
dent growth of mouse epidermal JB-6 cells stimulated with epidermal 
growth factor (10). Capsaicin, a major pungent principle of hot chili 
pepper (Capsicum annuum L., Solanaceae) with potential anti-inﬂam-
matory and anti-tumor promoting properties, also suppressed TPA-in-
duced activation of NF-κB in mouse skin in vivo (11). It also induces 
apoptosis in cancerous cells (12). Resveratrol, a phytoalexin present in 
grapes and red wine, inhibited TPA-induced phosphorylation of IκBα 
and subsequent p65 nuclear translocation by blocking IKKα and IKKβ 
(13). It also blocked the TCDD-induced expression of CYP1A1 and 
CYP1A2 in MCF10A cells, thereby reducing the formation of catechol 
estrogens from 17-beta estradiol (14). A recent study from my labora-
tory has revealed that resveratrol protects against oxidative PC12 cells 
by inducing Nrf2-driven expression of heme oxygenase-1 (15). The 
green tea polyphenol EGCG also inhibited activation of NF-κB and AP-
1 thereby suppressing the COX-2 induction in mouse skin in vivo and/or 
cultured human mammary epithelial (MCF10A) cells (16). EGCG also 
upregulated antioxidant enzymes by activating the Nrf2-ARE signal-
ing pathway. Cysteine thiols present in various transcription factors and 
their regulators are recognized to function as redox sensors involved 
in ﬁne-tuning of transcriptional regulation of many genes essential for 
maintaining cellular homeostasis. Thus, oxidation or covalent modiﬁca-
tion of thiol groups present in redox-sensitive transcription factors and 
their regulating molecules can provide a unique strategy for molecular 
target-based chemoprevention and cytoprotection with anti-inﬂamma-
tory and antioxidant phytochemicals (17,18). 
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Lung cancer has been the most common cancer worldwide since 1985. 
It is the leading cause of cancer death in the world. Close to 90% of 
lung cancers are caused by tobacco smoking. Smoking cessation un-
fortunately does not eliminate the risk of lung cancer. In fact, over 50% 
of newly diagnosed lung cancers are now found in former smokers. 
The lack of effective therapy underscores the urgency to explore new 
frontiers of management, such as chemoprevention. Chemoprevention 
refers to the use of speciﬁc agents to reverse, suppress, or prevent the 
process of carcinogenesis. 
Based on epidemiological or preclinical data, several phase III lung 
cancer chemoprevention trials involving beta-carotene, vitamin A, 
E, 13-cis retinoic acid and N-acetylcysteine had been conducted but 
none had demonstrated beneﬁcial results. To facilitate the evaluation 
of promising agents, focus is now turning toward phase II studies 
with assessment of surrogate endpoint biomarkers (SEBM) of lung 
carcinogenesis. With understanding of important cellular signaling 
pathways involved in malignant transformation, various agents capable 
of modulating carcinogenic pathways are currently under active 
investigation. This presentation summarizes ongoing chemopreventive 
trials sponsored by the National Cancer Institute, many of which entail 
modulations of the ecosanoid signaling pathway, with a focus on stud-
ies involving COX-2 inhibition.
Eicosanoids are lipid metabolites that derive their names from their 
common origin, the eicosaenoic acids, which are C20 polyunsaturated 
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fatty acids. The major precursor Arachidonic acid (all-cis-5,8,11,14-
eicosatetraenoic acid) is metabolized to prostaglandins (PG) and prosta-
cyclin (PGI) by the cyclooxygenase (COX) pathway, while leukotri-
enes are formed via the lipoxygenase (LOX) pathway. These down 
stream lipid metabolites are thought to be involved in carcinogenesis, 
and ample preclinical ﬁndings support modulations of arachidonic acid 
pathways for inhibition of carcinogenesis. There are two main isoforms 
of COX: COX-1 and COX-2. COX-1 exists in most cells and is consti-
tutively active. In contrast, COX-2 is an inducible enzyme that is up-
regulated by carcinogens, inﬂammatory and mitogenic stimuli. COX-2 
is primarily responsible for the overproduction of PG in inﬂamed, as 
well as neoplastic tissues. Overproduction of PGE2 is associated with 
a variety of carcinogenic mechanism, including abnormal expression 
of epithelial growth factors, epithelial and microvascular proliferation, 
resistance to apoptosis and inhibition of antitumor immunity.
COX-2 expression has been demonstrated in premalignant bronchial 
tissue and lung cancer. Patients with higher levels of COX-2 expres-
sion in their tumors have a poorer prognosis. In murine models, COX-2 
inhibition impedes lung tumorigenesis, decreases the rate of growth of 
lung cancer and number and size of metastasis. Expression of COX-2 
has been shown to enhance tumorigenesis by regulation of angiogen-
esis via CXC chemokines and EGFR, invasion via CD44 and matrix 
metalloproteinases, apoptosis via survivin and insulin like growth 
factor, and anti-tumor immunity via IL-10 and IL-12. Several clini-
cal trials addressing the use of Celecoxib for lung cancer prevention 
are underway. Results of a pilot, phase IIa trial in high-risk smokers 
performed at UCLA suggest that Celecoxib may modulate SEBM with 
reduction of PGE2 production, restoration of anti-tumor immunity and 
reduction of proliferation indices (Ki-67 labeling index). A follow-up 
larger phase IIb trial focusing on heavy former smokers is evaluating 
the effect of Celecoxib on cellular and molecular events associated with 
lung carcinogenesis. Another phase IIb trial of Celecoxib in current and 
former smokers is being conducted at MD Anderson Cancer Center. 
Moreover, A multicenter study with the lead center at Mayo Clinic us-
ing Sulindac, a nonspeciﬁc COX inhibitor, is also recruiting patients. 
5-lipooxygenase (LOX) is an enzyme involved in the conversion of 
arachidonic acid to leukotrienes. Leukotrienes have been implicated to 
play a prominent inductive role in lung carcinogenesis. This is based on 
data demonstrating that 5-LOX is expressed in lung cancers and 5-LOX 
inhibitors reduced the multiplicity and incidence of lung tumors in 
mice. A Phase II Clinical trial of the 5-LOX inhibitor Zileuton has been 
conducted at the Karmanos Cancer Institute addressing the effect of 
Zileuton on bronchial dysplasia and multiple SEBM in at-risk smokers 
or patients with curatively treated aerodigestive cancers.
Another arachidonic acid metabolite of interest is prostacyclin (PGI). 
It has been demonstrated that up-regulation of PGI decreased tumori-
genicity in mice exposed to carcinogens. A multicenter study with the 
lead center at the University of Colorado is currently enrolling smokers 
and ex-smokers with sputum atypia in a phase II randomized clinical 
trial to evaluate the effectiveness of Iloprost, a synthetic analog of PGI. 
Endpoints include comparisons of phenotypic modulation of bronchial 
epithelium between the two groups, as well as evaluation of multiple 
SEBM. 
Numerous clinical studies evaluating promising agents in lung cancer 
chemoprevention are underway. Important goals for future chemopre-
vention trials include devising strategies to minimize toxicity, identify 
and validate appropriate SEBM. To this end, integration of new diag-
nostic technologies such as ﬂuorescence bronchscopy and spiral CT, 
molecular proﬁling of risks, using high-throughput technology such 
as genomics microarray and proteomics, for therapeutic stratiﬁcation 
and monitoring, will collectively facilitate the development of effective 
paradigms for prevention, early detection and treatment of lung cancer. 
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Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) given concurrently with chemotherapy do not improve patient 
outcomes compared to chemotherapy alone in advanced non-small cell 
lung cancer (NSCLC). One potential explanation for this lack of beneﬁt 
is a negative interaction or antagonism between chemotherapy and 
EGFR TKIs when delivered concomitantly. Support for this line of rea-
soning is provided by preclinical data demonstrating that EGFR TKIs 
induce primarily a cytostatic effect resulting from a G1 cell cycle arrest 
in cell lines with wild type (WT) EGFR, reducing cell cycle phase-de-
pendent activity of chemotherapy, whereas they induce apoptotic cell 
death in tumors with EGFR activating mutations. Thus, sequence-spe-
ciﬁc interactions of EGFR TKI-chemotherapy combinations may nega-
tively inﬂuence the efﬁcacy of these regimens in patients with NSCLC. 
Preclinical and clinical rationale for studies examining the concept of 
pharmacodynamic separation as a means for overcoming hypothesized 
antagonism of EGFR TKIs and chemotherapy as well as recent clinical 
trial results will be discussed.
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In the last years the identiﬁcation of a number of molecular targets 
essential and speciﬁc for tumor growth, cell proliferation and metas-
tasis development has produced a new class of anticancer drugs, the 
molecular targeted therapies.
Molecular biology has clearly identiﬁed many different tumoral meta-
bolic pathways which are active and crucial to neoplastic phenotype 
across different histologic solid tumors. Among these, the HER family 
receptors and neoangiogenesis have been particularly studied and a 
number of new drugs that inhibit speciﬁc growth factors such as epi-
dermal growth factors (EGF) and vascular endothelial growth factors 
(VEGF) have been developed through phase I-II-III trials as single 
agents or in combination with chemotherapy and some have been 
already registered for the treatment of advanced Non Small Cell Lung 
Cancer (NSCLC).
Among many factors related in promoting angiogenesis, Vascular 
Endothelial Growth Factor (VEGF) has a recognized critical rate-limit-
ing role because of its ability to regulate key steps in the angiogenesis 
